Investment Rating - The report maintains an "Outperform" rating for the Hong Kong stock market [4] Core Views - The market is experiencing high volatility with significant sector differentiation, particularly with innovative drugs performing strongly while the automotive sector has seen notable declines [1][2] - Overall, the Hang Seng Index increased by 0.4%, while the Hang Seng Technology Index decreased by 0.9% [1] - The report highlights that 19 industries within the Hong Kong Stock Connect saw gains, while 11 experienced losses, with the most significant increases in the comprehensive, pharmaceutical, and defense sectors [1] Summary by Sections Market Performance - The Hang Seng Index closed at 23,893, reflecting a weekly increase of 0.4% and a year-to-date increase of 19.1% [12] - The small-cap stocks outperformed mid and large-cap stocks, with the Hang Seng Small Cap Index rising by 4.5% [1] Fund Flow - There was a significant outflow of funds from the automotive sector, with an average daily outflow of HKD 17.7 billion, while the pharmaceutical sector saw an inflow of HKD 4.8 billion [2] - The overall average daily fund intensity for Hong Kong Stock Connect components was -8.0 billion HKD, indicating a shift from the previous week’s positive inflow [2] Earnings Forecast - The report indicates a substantial upward revision in earnings per share (EPS) expectations, particularly for the automotive sector, which saw a 24.3% increase [3] - In total, 26 industries had their EPS forecasts revised upward, while only 3 experienced downward revisions [3] Sector Performance - The comprehensive sector led with a 19.2% increase, followed by pharmaceuticals at 8.5% and defense at 8.1% [16] - The automotive sector, however, faced a decline of 4.4%, reflecting ongoing challenges within the industry [16]

Investment Rating - The report maintains a "Positive" investment rating for the industry [8]. Core Insights - IL-25 is identified as a novel target in the Type II inflammation pathway, showing upregulation in atopic dermatitis (AD), psoriasis, and contact dermatitis, indicating its involvement in the progression of these skin inflammatory diseases [2][5][27]. - The drug SM17, developed by Chinese Antibody, is a first-in-class (FIC) IL-17RB monoclonal antibody targeting IL-25, demonstrating promising proof-of-concept (PoC) data in Phase Ib trials for atopic dermatitis, with superior itch relief compared to existing therapies [6][35][42]. Summary by Sections IL-25 as a Target - IL-25, a member of the IL-17 cytokine family, plays a crucial role in host defense and inflammatory diseases, inducing the production of IL-4, IL-5, and IL-13, while inhibiting Th17 differentiation [5][17]. - The upregulation of IL-25 in various skin inflammatory diseases suggests its potential for multi-indication exploration [27]. SM17 Clinical Data - In the Phase Ib trial, 75% of patients in the high-dose group achieved at least a 75% improvement in the Eczema Area and Severity Index (EASI-75) by week 12, compared to 0% in the placebo group, indicating a significant difference of 75% [6][35]. - The high-dose group also showed that 91.7% of patients had a significant reduction in the Peak Pruritus Numeric Rating Scale (PP-NRS) score, with no responders in the placebo group [7][38]. - SM17 demonstrated rapid and deep itch relief, outperforming existing AD therapies while maintaining comparable skin lesion improvement [41][43]. Competitive Landscape - Currently, only two IL-25-targeting candidates, SM17 and XKH001, are in clinical development, indicating a relatively early stage of research for this target compared to more established pathways like IL-17 and IL-4 [6][33]. - The competitive landscape for IL-25 and IL-17RB-targeting drugs is evolving, with several candidates in various stages of development [34].

M&A Dynamics - From June 3 to June 8, there were 63 merger and acquisition (M&A) events involving listed companies, with 16 classified as significant M&A events[9] - Out of the total M&A events, 9 were completed, including 1 significant M&A[9] Policy Updates - The People's Bank of China emphasized the need to optimize systems for listings, M&A, and equity incentives based on technological innovation characteristics[7] - The Shanghai Stock Exchange plans to encourage listed companies to increase dividend payouts and enhance market value management tools[7] Major M&A Events - Notable M&A transactions included Baota Industrial acquiring 100% of Electric Power Investment New Energy for CNY 80,927,000[13] - A total of 4 M&A events involved state-owned enterprises as acquirers during the reporting period[13] M&A Failures - There were 3 failed M&A attempts, including a significant transaction by Guangdong Hongyuan due to a lack of consensus on the final transaction plan[15][17] - The failed transactions involved a total value of CNY 19,800,000 for one of the deals[17] Control Changes - Three companies reported changes in actual control, including Jinzi Ham and Diou Home, with the changes occurring between May 30 and June 5, 2025[19] Market Performance - The restructuring index underperformed the Wind All A index by -0.12% during the reporting period[21] - Over a mid-term view, the restructuring index showed fluctuations within a positive range compared to the Wind All A index[21] Risk Factors - Economic recovery in China is slower than expected, which may increase market uncertainty[26] - Geopolitical risks and uncertainties regarding U.S. policies towards China could negatively impact A-share liquidity[26]

Investment Rating - The report maintains an "Outperform" rating for the Hong Kong stock market [4] Core Insights - The Hong Kong stock market has shown a positive trend with the Hang Seng Index and Hang Seng Tech both increasing by 2.2% this week, indicating a strong performance in the innovation drug and internet sectors [1][12] - There has been a significant inflow of funds into Hong Kong stocks, particularly in the media and pharmaceutical sectors, with an average daily fund strength of +7.4 million HKD, a notable increase from the previous week [2] - Earnings per share (EPS) expectations for the Hong Kong stock market have been revised upward by 0.3%, with the electronics sector leading the revisions [3] Summary by Sections Market Performance - The Hang Seng Index closed at 23,793, reflecting a weekly increase of 2.2% and a year-to-date increase of 18.6% [12] - The performance of various sectors shows that the innovation drug sector rose by 6.1%, while the internet sector increased by 3.5% [1] Fund Flow Analysis - A total of 23 sectors experienced fund inflows, with media and pharmaceuticals seeing the highest inflows of +1.9 million HKD and +1.4 million HKD per day, respectively [2] - The sectors that faced outflows included transportation and home appliances, each with a daily outflow of -0.1 million HKD [2] Earnings Forecast - The overall EPS forecast for the Hong Kong stock market has been adjusted upward by 0.3%, with the electronics sector seeing a 1.1% increase in EPS expectations [3] - The steel sector, however, faced a significant downward revision of -7.7% in EPS expectations [3]

Summary of Key Points from the Conference Call Industry Overview - The conference call discusses the performance of the Hong Kong stock market (港股) in 2024, highlighting a recovery trend in overall earnings growth with a 1.2% increase in revenue and a 9.8% year-on-year growth in net profit attributable to shareholders [1][3][6]. Core Insights and Arguments - **Earnings Growth**: The second half of 2024 saw a significant acceleration in earnings, with a year-on-year increase of 13.3% [1][6]. - **Key Sectors Driving Growth**: - The information technology sector benefited from breakthroughs in AI technology, with net profit growth of 77.4% in the software and services sub-sector and 76.4% in the technology hardware and equipment sub-sector [1][10]. - The financial sector, particularly the insurance industry, experienced a 70.8% increase in net profit, while diversified financial services saw a 20.5% growth [1][10]. - The healthcare sector, including pharmaceuticals, biotechnology, and life sciences, improved profitability by nearly 20 percentage points [1][10]. - **Struggling Sectors**: The consumer sector showed weak growth, with significant declines in return on equity (ROE) for household and personal products, and food retail. The optional consumer retail sub-sector's profit growth decreased by 36 percentage points, while media and consumer services saw declines of approximately 18% and 19% respectively [1][11]. Financial Metrics - **Return on Equity (ROE)**: The ROE for Hong Kong stocks rose to 7% in 2024, up from 6.7% in the first half of the year, but still below the average of around 10% since 2016. The DuPont analysis indicated that the increase in asset turnover was the primary driver of the ROE improvement [1][7][8]. - **Revenue Trends**: The revenue growth rate for Hong Kong stocks showed signs of bottoming out, with a 1.2% increase for the year, slightly down from 1.9% in the first half of 2024 [1][5]. Comparative Analysis - **Performance vs. A-shares**: The earnings recovery speed of Hong Kong stocks is superior to that of A-shares, which reported negative growth rates of -0.2% for the year and -0.5% for the first half of 2025 in terms of revenue and -2.7% for both periods in net profit [4][6]. Future Outlook - **Support Factors for 2025**: The global technology cycle is expected to rebound, with the AI-driven industrial revolution continuing to support the performance of the information technology sector. Additionally, macroeconomic policies aimed at stabilizing growth are anticipated to benefit mainland companies, which constitute over 60% of the market [4][12].

[Table_Info1] 证券研究报告 [Table_Title] 证券研究报告 / 债券研究报告 2025 年 5 月十大转债 报告摘要： [Table_Summary] 5 月十大转债如下： 中证转债指数 [Table_Report] 相关报告 《2025 年 4 月转债新券点评合集》 --20250430 《特朗普还有哪些牌？》 --20250428 《转债市场一周回顾（2025/04/21-2025/04/25）》 --20250427 《关税冲击逐步显现，"四稳"兜牢民生底线— —政策及基本面周度观察（20250426）》 --20250427 《【东北资产配置】政策博弈期，大类资产怎么 看？——东北证券大类资产配置报告（第 5 期）》 --20250425 首席分析师：刘哲铭 执业证书编号：S0550524040002 18801785199 liuzm1@nesc.cn 证券分析师：薛进 [Table_Invest] [Table_Author] ① 中特转债（AAA，4 月末收盘价 107.723 元，转股溢价率 111.03%， 正股 PE-TTM 11.5） ② 山路转债（AAA，4 月 ...